Cardiac assessment in Australian patients receiving (neo)adjuvant trastuzumab for HER2-positive early breast cancer: a population-based study

被引：0
|
作者：
Monica Tang
Andrea L. Schaffer
Belinda E. Kiely
Benjamin Daniels
Chee K. Lee
Robert J. Simes
Sallie-Anne Pearson
机构：
[1] University of New South Wales,Centre for Big Data Research in Health
[2] University of Sydney,NHMRC Clinical Trials Centre
来源：
Breast Cancer Research and Treatment | 2021年 / 187卷
关键词：
Breast neoplasms; Human epidermal growth factor 2; Trastuzumab; Heart function tests; Observational study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：893 / 902
页数：9
相关论文
共 50 条
  • [41] First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab
    Vaglica, M.
    Lambertini, M.
    Ferreira, A.
    Poggio, F.
    Puglisi, F.
    Sottotetti, F.
    Montemurro, F.
    Poletto, E.
    Pozzi, E.
    Risi, E.
    Lai, A.
    Zanardi, E.
    Sini, V.
    Ziliani, S.
    Minuti, G.
    Mura, S.
    Grasso, D.
    Ferrarini, I.
    Pronzato, P.
    Del Mastro, L.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S286 - S286
  • [42] Are neutrophil/lymphocyte ratio and platelet/lymphocyte ratio associated with prognosis in patients with HER2-positive early breast cancer receiving adjuvant trastuzumab?
    Ulas, Arife
    Avci, Nilufer
    Kos, Tugba
    Cubukcu, Erdem
    Olmez, Omer Fatih
    Bulut, Nilufer
    Degirmenci, Mustafa
    JOURNAL OF BUON, 2015, 20 (03): : 714 - 722
  • [43] Use of trastuzumab for HER2-positive metastatic breast cancer in daily practice: a population-based study focusing on the elderly
    van Rooijen, Johan M.
    de Munck, Linda
    Teeuwen, Guusje M.
    de Graaf, Jacques C.
    Jansman, Frank G.
    Boers, James E.
    Siesling, Sabine
    ANTI-CANCER DRUGS, 2016, 27 (02) : 127 - 132
  • [44] CARDIOTOXICITY OF ADJUVANT TRASTUZUMAB IN EARLY STAGE, HER2-POSITIVE, BREAST CANCER PATIENTS TREATED WITH PRIOR ADJUVANT ANTHRACYLINE-BASED CHEMOTHERAPY
    Ratti, Riccardo
    Coccorullo, Zaira
    Guarneri, Domenico
    Colloca, Giuseppe
    Venturino, Antonella
    Addamo, Gianfranco
    Campora, Elisabetta
    ANNALS OF ONCOLOGY, 2009, 20
  • [45] CARDIOTOXICITY OF ADJUVANT TRASTUZUMAB IN EARLY STAGE, HER2-POSITIVE, BREAST CANCER PATIENTS TREATED WITH PRIOR ADJUVANT ANTHRACYLINE-BASED CHEMOTHERAPY
    Ratti, R.
    Coccorullo, Z.
    Guarneri, D.
    Colloca, G.
    Addamo, G.
    Venturino, A.
    Campora, E.
    ANNALS OF ONCOLOGY, 2009, 20 : 45 - 45
  • [46] Resumption of Trastuzumab in Patients With Disease Recurrence After (Neo-) Adjuvant Anti-HER2-therapy in Patients With HER2-positive Breast Cancer
    Hanker, Lars Christian
    Foerster, Frank
    Schroeder, Jan
    Grafe, Andrea
    Hitschold, Thomas
    Hesse, Tobias
    Lattrich, Claus Richard
    Rody, Achim
    ANTICANCER RESEARCH, 2020, 40 (07) : 3973 - 3981
  • [47] Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer
    Hudis, CA
    NATURE CLINICAL PRACTICE ONCOLOGY, 2006, 3 (01): : 12 - 13
  • [48] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [49] Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?
    Santini, Daniele
    Vincenzi, Bruno
    Tonini, Giuseppe
    WOMENS HEALTH, 2006, 2 (01) : 1 - 3
  • [50] Trastuzumab adds to adjuvant chemotherapy for resected HER2-positive breast cancer
    Clifford A Hudis
    Nature Clinical Practice Oncology, 2006, 3 : 12 - 13
12345